Astellas Pharma, Inc.
9.51USDD
+0.10+1.06%
At close at Jul 11, 19:59 GMT
USD
No trades
Next report date
July 30
Report period
Q1 2025
EPS estimate
0.12 USD
Revenue estimate
3.24 B USD
0.19 USD
332.88 M USD
12.54 B USD
1.79 B
About ASTELLAS PHARMA
Sector
Industry
CEO
Naoki Okamura
Website
Headquarters
Tokyo
Founded
1923
FIGI
BBG000NVS6W6
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products: XTANDI, PADCEV, XOSPATA, VYLOY, VEOZAH, IZERVAY, EVRENZO, BETANIS and PROGRAF. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
−20%
−10%
0%
10%
20%
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
−1.20 B
0.00
1.20 B
2.40 B
3.60 B
Revenue
Net income
Net margin %
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
0.00
800.00 M
1.60 B
2.40 B
3.20 B
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
0.00
800.00 M
1.60 B
2.40 B
3.20 B
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
0.00
2.00 B
4.00 B
6.00 B
8.00 B
Debt
Free cash flow
Cash & equivalents
No news here
Looks like there's nothing to report right now
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.